BioNTech SE (BNTX)

151.54
+10.82(+7.69%)
After Hours
150.95
-0.59(-0.39%)
- Real-time Data
  • Volume:
    4,624,324
  • Bid/Ask:
    150.50/152.00
  • Day's Range:
    141.49 - 152.32

BNTX Overview

Prev. Close
140.72
Day's Range
141.49 - 152.32
Revenue
583.49M
Open
141.49
52 wk Range
39.8 - 152.32
EPS
-0.4
Volume
4,624,324
Market Cap
36.6B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,873,970
P/E Ratio
N/A
Beta
0
1-Year Change
271.33%
Shares Outstanding
241,521,065
Next Earnings Date
Nov 30, 2
What is your sentiment on BioNTech SE?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE News

BioNTech SE Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
1941

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Read More
  • scam stock. should be $100
    1
    • Deserves 300. at least.
      3
      • Based on selling 2.5b vaccines in 21 then 2.4b in 22 and again in 23, a share price of $240 would be fair value, excluding any other products brought to market in the interim.
        0
    • for sure this will be more than Moderna in 1 week! Just have patience and monitoring the nice graphic!
      1
      • The Guardian: Moderna struggling to supply promised doses of Covid vaccineThe Guardian: Moderna struggling to supply promised doses of Covid vaccine.https://www.theguardian.com/world/2021/apr/16/moderna-struggling-to-supply-promised-doses-of-covid-vaccine
        0
    • at 180 it would be fairly priced
      0
      • if next revenue report will be as it is supposed to be, I think could be possible 180
        0
      • Fab Piwhen is the next revenue report?
        0
      • seems 10th may
        0
    • Isn’t it strange it is lower than let’s say tesla for example or others which is saving lifes??.. that figure blow of my mind nowadays. Not just for this stock. For moderna or other health stocks too..
      0
      • what?
        0
    • crazy! astrazenaca and JnJ are failing, Bntx should fly above 150 but we are still on low volumes
      0
      • Low volumes? Look at the march levels and tell me why are low
        0
    • still very cheap
      0
      • https://seekingalpha.com/news/3680226-astrazeneca-vaccine-woes-could-derail-global-vaccination-drive
        0
        • Pfizer did not develop this vaccine, yet enjoys half of its profits, but with the proceeds of this year Biontech does not need Pfizer as badly as the year before, especially not for anything Covid related
          1
          • this stock is ridiculously cheap... for how long?
            0
            • I agree. The company already has sales of at least 10 B from contracts for this year, and market capitalization only 25 B. A study has now been published that it is 91% effective against the South African variant. Astra Zenec from South Africa was sold by their government / 1 million doses /, because it did not work for them there for this variant !! In addition, they have a lot of onco preparations in the study phase, from melanoma to lung cancer.
              0
            • Guys do you know when earnings will be published?
              0
            • For 1Q in May
              0
          • i think Pfizer is the best choice . what do you think?
            4
            • BNTX is going only one way...order book will only increase. Canada and Germany suspend Austrazeneca, BNTX to file for FDA approval for teenager's and production capacity increased to 2.5 billion doses leaving 1.1 billion in unclaimed capacity or $11 billion in additional BNTX revenue.
              0
          • I agree. And we also have to start vaccination of third world countries from an ethical code and for our safety concerning mutations and variants.
            0
            • This could be the cheapest listed share on the market.
              0
              • From my medical point of view, what we know about coronavir so far: 1. We will never get rid of coronavirus COVID 19. 2. As with the flu, we will have to be vaccinated repeatedly. 3. In the second period, the children will have to be vaccinated. 4. In the near future, only vaccines with 94% efficacy and higher will be vaccinated. Why is Biotech a great and best choice? It already has advanced studies in children on safety, with Modern's highest efficacy, and unlike Adenovirus carriers — their MRNA technology allows for repeated use with minimal side effects.
                0
                • this company projects 10 bn dollars in income from one product alone, yet it is valued at 25 bn
                  0
                  • yes, +634,91% income!!
                    0
                • Q4 Sales 345.4MNet profit 366.9Mhttps://www.globenewswire.com/news-release/2021/03/30/2201363/0/en/BioNTech-Announces-Full-Year-2020-Financial-Results-and-Corporate-Update.html
                  0
                  • https://www.marketwatch.com/story/biontechs-marburg-facility-gets-ema-approval-boosting-covid-19-vaccine-production-capacity-by-a-billion-doses-a-year-2021-03-26?mod=investing
                    0
                    • Biontech / Pfizer best vaccine. I am a doctor and all my colleagues and I have been vaccinated with their vaccine / low risk and 20% higher effectiveness of 75% x95% against COVID than, for example, ASTRA Zeneca /. In addition, it develops very promising mRNA oncological preparations for melanoma, lung cancer and ovarian cancer and others. I believe that the price target of around 130 to 4 months is justified.
                      1
                      • Listen to my man Are we are moooooooning 🚀🌝🪐😎🦍🦍🦍
                        1
                    • Only company im adding together with Sony
                      0
                      • Bananas on sale 🍌🍌🍌🚀🚀🚀🌝🪐🦍🦍🦍
                        0
                        • Me like two digit numbers 🦍Me buying more🦍🌝🪐🚀😎
                          0
                          • Will be back to 131 and beyond... 🚀🚀🚀🚀🚀🚀🚀
                            0
                            • is this all the short can do only 4,5%? thank you added more 50 sheres cheaper...keep pushing down and i will buy even more 😎🚀
                              0
                              • i like round numbers 100 but i like more 110 I'm a rocket scientist 🚀🚀🚀🚀🌝🪐
                                0
                                • Go Bio!!! 🚀🚀🚀🚀🚀🚀🚀
                                  0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.